Cellceutix Antibiotic Brilacidin Chosen by Elsevier as "Top Project to Watch" in Infectious Disease
October 10 2013 - 7:00AM
Marketwired
Cellceutix Antibiotic Brilacidin Chosen by Elsevier as "Top Project
to Watch" in Infectious Disease
BEVERLY, MA--(Marketwired - Oct 10, 2013) - Cellceutix
Corporation (OTCQB: CTIX) (the "Company"), a clinical stage
biopharmaceutical company focused on discovering, developing and
commercializing drugs to treat unmet medical conditions, is pleased
to announce that the publishers of pharmaceutical publications In
Vivo, Startup, and The Pink Sheet have chosen Brilacidin Phase II
ABSSSI as a "Top Project to Watch." This represents a significant
industry honor. Many of the past nominees include those who
partnered successfully such as Trophos, BiPar, Myogen, Sirtris and
Kosan. Cellceutix, as recipient of this honor, will be presenting
at the Elsevier Therapeutic Area Partnerships conference, being
held from November 18 - 20 at the Hyatt Regency in Boston,
Massachusetts. Cellceutix was selected by a panel of independent
experts to present information on Brilacidin, a promising clinical
stage antibiotic acquired by Cellceutix in September.
More information on the conference can be found at:
http://www.elsevierbi.com/mkt/Conf/TAP2013/PresentingCos.
Cellceutix and Brilacidin are listed under the "Infectious
Diseases" tab.
Cellceutix now has a dedicated team to advance the development
of Brilacidin for multiple indications. The Company is currently
working on two Investigational New Drug ("IND") applications for
clinical trials of Brilacidin. The first is for a Phase 2b trial to
further evaluate the antibiotic for Acute Bacterial Skin and Skin
Structure Infections, or ABSSSI. The second is for a Phase 2
clinical trial of Brilacidin as a new treatment for oral mucositis.
Both IND applications are planned for submission to the U.S. Food
and Drug Administration in January 2014.
"Now that we have spent substantial time with researchers that
were entrenched in the development of Brilacidin before we acquired
it, we are more excited than ever about the opportunities that lay
ahead of us," said Leo Ehrlich, Chief Executive Officer at
Cellceutix. "We are honored to have Brilacidin selected by Elsevier
as a Top 10 drug to watch in infectious disease and believe the
conference provides us with a valuable opportunity to meet with
potential partners. Looking back at the acquisition, we believe we
have completed one of the most promising biotech acquisitions in
recent years and intend to develop this asset to its absolute
maximum potential which we and outside consultants believe is
tremendous."
Mr. Ehrlich added, "Separately, I am very pleased to tell
investors that the Safety Review Committee overseeing the trial of
Kevetrin, our lead cancer compound in a Phase 1 clinical trial at
Dana-Farber Cancer Institute and Beth Israel Deaconess Medical
Center, has approved increasing the dosing of Kevetrin to 110 mg/m2
for the sixth cohort. We anticipate dosing to begin in the next
seven to ten days."
About Cellceutix
Headquartered in Beverly, Massachusetts, Cellceutix is a
publicly traded company under the symbol "CTIX". Cellceutix is a
clinical stage biopharmaceutical company focused on developing and
commercializing its pipeline of compounds for novel therapies in
areas of serious unmet medical need, including cancer, psoriasis
and antibiotic applications. More information is available on the
Cellceutix web site at www.cellceutix.com.
Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not
strictly historical, including statements as to revenue
projections, business strategy, outlook, objectives, future
milestones, plans, intentions, goals, future financial conditions,
future collaboration agreements, the success of the Company's
development, events conditioned on stockholder or other approval,
or otherwise as to future events, such statements are
forward-looking, and are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The forward-looking statements contained in this release are
subject to certain risks and uncertainties that could cause actual
results to differ materially from the statements made. Factors that
may impact Cellceutix's success are more fully disclosed in
Cellceutix's most recent public filings with the U.S. Securities
and Exchange Commission.
Cellceutix Corp. Leo Ehrlich (978) 236-8717 Email Contact
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Innovation Pharmaceuticals (CE) (USOTC:IPIX)
Historical Stock Chart
From Apr 2023 to Apr 2024